OBJECTIVES: China has formed a multi-level medical security system, in which the health insurance acts as the main body and social assistance as the support. However, the protection level of major diseases is still low and the range of protection is narrow. Drugs to orphan and major diseases are often of high price, and the existence of the problems that patients becoming poor due to diseases, and becoming poor again due to diseases is still troublesome. In this paper, we study the feasibility of establishing a multi-party co-payment system for patients with such diseases, and put forward opinions and suggestions on the accessibility of high-value drugs.

METHODS: Four methods: search in document data basement, surveys (52), and interviews with experts and discussions with focus group.

RESULTS: Major diseases have certain similarities and drugs to these diseases are of usually high price, families of patients who need long-term use of drug, can’t usually afford the annual cost of drugs.This study focuses on the analysis of charitable participation in high-value drug co-payment protection mechanism, linking up health insurance, medical assistance and social charity and so on. By collecting information on domestic and international research, interviews with experts and scholars as well as research questionnaire content, forming a co-payment security mechanism with health insurance fund as the main body; commercial insurance, medical assistance and social charity working together, which could reduce the burden on patients, so that patients can afford high value drugs.

CONCLUSIONS: The research shows that more than 86.7% of the people are for the establishment of co-payment mode to protect the patients of major diseases. But experts also pointed out that in the current stage of China's health insurance, the financing capacity is insufficient, the participation of commercial insurance is low. The implementing of high-value drugs co-payment mechanism requires the promotion in national level.